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In 1966, Michielsen and Lambert [1] introduced
the nonsteroid antlinflammatory drug indomethacin
in the treatment of glomerulonephritis and demon-
strated that the drug can reduce proteinuria in pa-
tients with the nephrotic syndrome. Similar effects
on proteinuria had been reported for amino-
phenazone and phenylbutazone [2-4] and, sub-
sequently, oxyphenbutazone [5]. Although these
observations have been elaborated in detail by
Michielsen et al [6—9] and others [10—17], the effect
has so far remained unexplained.
A first possibility is that indomethacin limits the
pathologic process in the glomeruli. Michielsen et al
advocate this possibility, both on morphologic
grounds [7] and by analysis of protracted followup
studies on patients with chronic membranoprolifer-
ative glomerulonephritis [9]. Their findings, how-
ever, have not, so far, been confirmed by others [5,
11]. In lupus nephritis, there may be a favorable ef-
fect of long-term indomethacin treatment, alone or
in combination with corticosteroids [5] or chloro-
quine derivations [12, 18].
A second possibility is that indomethacin exerts
its effects on proteinuria by influencing renal func-
tion. The effect on proteinuria is nearly always vis-
ible on the first day of indomethacin treatment and
disappears within a day or, at most, a few days after
the drug is discontinued. This effect is often accom-
panied by a reversible decrease in endogenous
creatinine clearance and a decreased diuresis with
retention of sodium and other solutes [5, 19]. Indo-
methacin also is reported to cause immediate,
marked inactivation of even strong diuretics such as
furosemide [20, 21] and bumetamide [22] in dogs.
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This phenomenon has been found also in patients
with the nephrotic syndrome [23]. These observa-
tions suggest that the effect on proteinuria may be
explicable by an influence on renal function. In this
context, the role of indomethacin as a prostaglandin
synthetase inhibitor may be important [24, 25]. Evi-
dently, the renal prostaglandins play an important
role in the regulation of renal blood flow [26-28]
with an effect related but contrary to the activity of
the renin-angiotensin system [29-31].
A third possibility to explain the effect of indo-
methacin could be an influence on permeability of
the glomerular basement membrane, either via a
change in characteristics of the molecular sieve or
via a change in the electrical charge of the glomeru-
lar polyanion [32]. Such an effect may be aug-
mented by changes in intrarenal blood flow, as the
permeability of the glomerular basement membrane
is dependent, not only on the structure and electri-
cal charge of the membrane, but also on hemo-
dynamic factors [33—40]. As long as filtration equi-
librium exists or as filtration fraction (FF) is con-
stant, ultrafiltration and diffusion are largely depen-
dent on glomerular plasma flow. Recent studies on
fractional clearances of dextran molecules show
that permeability decreases with increasing plasma
flow and decreasing FF, and vice versa [41].
The second and the third possibilities may be
interrelated via redistribution of RBF as mediated
by the renin-angiotensin system and the renal
prostaglandins. Redistribution of the RBF to a
nephron population with a different permeability
to macromolecules (as, for example, the juxtamed-
ullary nephrons) may be an explanation for the ef-
fect of indomethacin on proteinuria. Until now,
there has been no indication that the structure of
the glomerular basement membrane expressed in
terms of pore radius, or the electrical charge, of
juxtamedullary nephrons differs from these perme-
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ability-determining factors in superficial cortical
nephrons. Nevertheless, juxtamedullary glomeruli
in different species of mammals are known to be
larger and to have a relative higher GFR than do
the superficial glomeruli [42—45]. Perhaps this dif-
ference in capacity induces alterations in the ratio
between GFR and RPF, when blood flow is re-
distributed to the juxtamedullary glomeruli, leading
to disequilibrium, a decrease in FF and a decrease
in permeability for macromolecular substances.
The FF in superficial glomeruli seems to be greater
than it is in juxtamedullary ones [46-50], and in-
domethacin decreases FF in patients with the neph-
rotic syndrome, possibly by redistribution of the
RPF to juxtamedullary nephrons, but in any case
by influencing GFR more than RPF [19]. If the
glomerular permeability to macromolecules is influ-
enced by indomethacin interfering with the renal
prostaglandins and the renin-angiotensin system, a
quantitative decrease in proteinuria may be ex-
pected and, perhaps, also changes in the selectivity
of proteinuria. The last effect could then also be
demonstrated by fractional clearances of the inert
and neutral charged polydisperse polyvinylpyrroli-
done (PVP) molecules.
Thus, we investigated in a clinical study whether
there was an effect on glomerular permeability mea-
sured by differential protein clearances and frac-
tional PVP clearances in patients with a nephrotic
syndrome, and correlated these observations with
the effect on proteinuria and GFR.
Methods
Clinical procedure. All patients were hospital-
ized. Urine was collected daily in 24-hour portions,
at 8.00 A.M. Creatinine excretion was used as a con-
trol on urine collection and to calculate the endoge-
nous creatinine clearance. Proteinuria was deter-
mined per 24 hours. When given, a sodium-restrict-
ed diet contained 10 mmoles of sodium per 24
hours.
Two periods of 5 days, without and during indo-
methacin medication (50 mg three times daily) were
compared. Serum creatinine concentration and pro-
tein electrophoresis were determined on day 2 and
day 5 of each period, and the means of the values of
each period were compared. Serum and urine sam-
ples were simultaneously collected for differential
protein clearances on day 5 of each period. Frac-
tional PVP clearances were carried out also on day
5 of the period without and during indomethacin
medication. All patients in whom PVP clearances
were carried out, were given 180 mg of potassium
iodide daily from 3 days before the first injection of
1251-PVP to 8 days after the second injection. This
was done to prevent uptake of radioactive iodine
into the thyroid. One hour before PVP injection, the
test subjects were given 1000 ml of water to drink.
The bladder was emptied as thoroughly as possible
immediately before the injection. Blood samples
were collected 5, 60, and 120 mm after injection of 1
Ci of 1251 PVP per kilogram of body wt. A few min-
utes after collection of the second and third blood
sample, the test subject was asked to empty the
bladder as thoroughly as possible for the two
consecutive 1-hour clearances. Whenever a second
PVP clearance was done, the PVP injection was
preceded by collection of a blood sample for veri-
fication of possible residual activity of the pre-
viously injected PVP. No activity was registered in
these samples. After chemical analysis, the urine
samples of the first two 24 hours collected after PVP
injection were stored for controlled decay.
Laboratory procedures. Single radial immuno-
diffusion [51] was used to determine albumin, trans-
ferrin, IgG, and a2-macroglobulin, and selectivity
was expressed as the IgG:albumin clearance ratio
[52]. The coefficient of variation over the four
sample determinations required for calculation was
15.7%. Urine was concentrated for determination of
a2-macroglobulin only, by using positive-pressure
ultrafiltration over a Diaflo XM300 membrane. Pro-
tein loss by the concentrating procedure varied be-
tween 0 and 10.9%. The coefficient of variation in
the determination of a2-macroglobulin was 19.8%.
Urine protein concentration was determined by the
Biuret method; serum and urine creatinine concen-
tration, by an alkaline picrate method adapted to
the autoanalyzer. The polydisperse PVP (molecu-
lar-size range, 15 to 80 A) was fractionated from
blood and urine samples with gel filtration accord-
ing to the method described by Hulme and Hard-
wicke [53], with slight modifications. Biogel A (0.5
M, 200 to 400 mesh, was used instead of Sephadex
0200, in a 70 x 2.6-cm column (Pharmacia), and the
relation between molecular radius and elution vol-
ume was determined as log Rs = 0.9833 + 0.9262 (1
— Kay). We used as eluent a buffer solution of 0.1 M
Iris and 0.2 M sodium chloride in distilled water,
with 1 ml of 20% sodium azide per liter as pre-
servative. The flow rate was 30 mllhr, and the eluate
was collected in fractions of 2.5 ml (Ultrarac 7000
LKB). The fractions were counted for 5 mm in a
gamma-sample counter (LKB Wallac 80.000) to a
combined error of plasma and urine fractions of
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Table!. Effect of indomethacin on endogenous creatinine clearance and proteinuria in 33 patients
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Amyloidosis
Membranoproliferativeglomerulonephritis
Membranoproliferativeglomerulonephritis
Focal segmentalglomerulonephritis
Rejection
Focalsegmentalglomerulonephritis
Rejection
Amyloidosis
Mesangialproliferativeglomerulonephritis
Membranoproliferativeglomerulonephritis
Membranoproliferativeglomerulonephritis
Membranousglomerulonephritis
Segmentalproliferativeglomerulonephritis
Focal segmental glomerulonephritis
Intracapillaryglomerulonephritis
Focalglomerulonephritis
Focalsegmentalglomerulonephritis
Membranoproliferativeglomerulonephritis
Focalsegmentalglomerulonephritis
Amyloidosis
Focal segmentalglomerulonephritis
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Minimallesions
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Minimal lesions
85 88
75 75
107 64
118 120
34 34
68 65
44 40
95 68
95 53
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85 95
90 90
49 54
75 24
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96 94
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40 32
73 63
55 45
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2.2%. The duplicate error in fractional PVP clear-
ances was determined after informed consent in
three volunteers with normal renal function and
proved to be 5.2% on the intercept and 8.4% on the
slope of regression lines. The mean of the regres-
sion lines obtained in the first and the second 1-hour
clearance period was calculated. All the regression
lines had a high coefficient of correlation (—0.990 or
higher), and this is therefore not mentioned sepa-
rately. In the patients with an increased clearance
of PVP molecules larger than 40 A, the regression
lines for molecules smaller than 40 A were calcu-
lated, and for the larger fractions the means of the
clearance percentages of these fractions without
and during indomethacin were compared.
Patients. The effect of indomethacin on selectiv-
ity, proteinuria, and endogenous creatinine clear-
ance was studied in 33 patients (21 male and 12 fe-
male) between 18 and 72 years old. In 17 of these,
transferrin and 2-macroglobulin were also deter-
mined. In 28 patients, fractional PYP clearances be-
fore and during indomethacin medication were
studied, but in 4 of them no limiting urine to plasma
ratio could be calculated, and they were excluded.
Results
Effect of indomethacin on proteinuria and endog-
enous creatinine clearance (Table 1). For patient
10, there are no data available about proteinuria and
endogenous creatinine clearance prior to indometh-
acm medication, and this patient is partly excluded
from the study. Patient 33 had a mean proteinuria of
35.1 g124 hr, due to daily infusions of 250 ml of
plasma throughout the test period, also during indo-
methacin medication. As Table 1 shows, in all pa-
tients the proteinuria decreased during indometha-
cm medication. The mean proteinuria in 32 patients
was 9.2 (SD) 5.6 g124 hr and decreased to 4.6
3.8 g!24 hr. The mean decrease was 4.6 2.9 g124 hr
or 51 22%. There was no difference in the effect
between the 22 patients on a sodium restricted diet
and the 10 patients on a sodium-containing diet, al-
though the latter group had a mean proteinuria of
6.9 2.2 g/24 hr against 10.3 6.4 g!24 hr in the
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Endogenous Car, mi/mm
Fig. 1. Absence of a relation between the effect of indomethacin
on endogenous creatinine clearance and that on proteinuria.
former group. The mean decrease in proteinuria
was, respectively, 3.8 2.4 and 5.3 4.3 g124 hr in
both groups or 53 23% and 49 24%. There was
no significant difference in mean decrease in pro-
teinuria and in mean percentual decrease in the two
groups (Student's t test). In 20 of the 32 patients,
the endogenous creatinine clearance decreased; in 5
patients it remained constant and 8 patients showed
an increase. The mean percentual decrease in
creatinine clearance was 11 (SD) 18% for the en-
tire group, 10 20% for the sodium-restricted
group, and 13 18% for the unrestricted group.
Again, there was no significant difference in mean
changes of endogenous creatinine clearance or in
mean percentual changes between the two groups.
100
80
00
x 60
0
0
0
40
20
Control Indomethacin Control Indomethacin
Sodium-restricted Sodium-containing
diet diet
Fig. 2. Effect of indomethacin on selectivity in 23 patients on a
sodium-restricted and 10 on an unrestricted diet.
Table 2. Relative clearances of transferrin, IgG, and a2-macroglobulin expressed as percentage of albumin clearance, before and during
indomethacin (I) medicationa
Transferrin IgG a2-Macroglobulin —K r P 0Patient
no. Before During Before During Before During Before During Before During Before During Before During
15
> 10
5
20 40 60 80 100 120
When the decrease in proteinuria is plotted against
the effect on endogenous creatinine clearance (Fig.
1), no direct relation between the two effects is de-
monstrable. If it were, then all errors indicating the
decrease in proteinuria should also point to the in-
tersection of abcissa and ordinate.
Effect of indomethacin on selectivity (C10GJCaIb X
100) (Fig. 2). The effect on selectivity of proteinuria
1 80 88 4 13 0.1 0.1 2.82 2.86 —0.981 —0.997 0.05 0.01 70.5 70.7
2 147 96 25 27 3 2 1.52 1.62 —0.971 —0.995 0.05 0.01 57 58
5 129 110 27 32 0.1 0.5 2.94 2.24 —0.989 —0.991 0.01 0.01 71 66
6 119 101 25 6 2 4 1.66 1.30 —0.989 —0.835 0.05 NS 59 52
7 138 140 29 42 negative
12 53 85 18 17 negative
14 167 1.14 50 32 3 2 1.56 1.60 —0.976 —0.992 0.05 0.01 57 59
15 81 80 22 20 negative
20 82 91 14 10 0.9 0.2 1.92 2.57 —0.990 —0.992 0.01 0.01 62 69
21 37 109 28 97 0.2 0.2 2.44 2.65 —0.988 —0.957 0.05 0.05 68 69
23 117 103 27 30 3 2 1.49 1.64 —0.984 —0.994 0.05 0.01 56 59
25 125 200 20 4 1,1 1.3 1.91 1.88 —0.986 —0.886 0.05 NS 62 62
26 100 96 10 24 0.8 0.6 1.99 2.13 —0.974 —0.996 0.05 0.01 63 65
27 98 100 40 25 1 2 1.93 1.63 —0.991 —0.992 0.01 0.01 63 58
28 96 40 22 8 2.6 0.3 1.51 2.26 —0.987 —0.993 0.05 0.01 56 66
29 79 22 15 8 0.1 0.1 2.85 2.62 —0.997 —0.994 0.01 0.01 71 69
32 97 103 28 34 1.5 1.2 1.75 1.86 —0.996 —0.994 0.01 0.01 60 62
a 0 is angle of slope of regression line, calculated through the four points obtained by plotting the relative protein clearances against the
molecular weights on a double logarithmic scale, on the y axis and the x axis, respectively. K is minus the tangent 0.
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Control Indomethacin
Fig. 3, Differential protein clearance measured from albumin
and a2-macroglobulin (a2M) in 14 patients, without and during
indomethacin medication.
shows that selectivity increased in 16 of the 23 pa-
tients with a sodium-restricted diet and in only 3 of
the 10 patients with unrestricted diet. This effect on
selectivity is not significant in either group, al-
though it is more pronounced in the sodium-restrict-
ed-diet group.
Effect of indomethacin on selectivity measured
from albumin, transferrin, IgG, and a2-macroglob-
ulin. In 17 patients, transferrin and 2-macroglob-
ulin were determined, as well as albumin and IgG,
to establish whether determination of the former
two proteins might influence the data on selectivity
so far presented. When the relative clearances of
transferrin, IgG, and a2-macroglobulin are plotted
on a double logarithmic scale against molecular
weight, a regression line can be calculated from the
points obtained [54].
Table 2 lists the results of the relative clearances
of these proteins as a percentage of albumin clear-
ance without and during indomethacin medication.
There is a significant correlation between the loga-
rithms of the relative protein clearances and those
of their molecular weights, except in 2 patients dur-
ing indomethacin medication. Again there is no sig-
nificant difference before and during indomethacin.
The mean angle of slope before indomethacin is
62.5 (SD) 5.6% and during medication 63.2
Molecular radius, A
Fig. 4. Permeability slopes for PVP in three patients, without
and during indomethacin medication (normal type).
5.5%. Even when a2-macroglobulin is omitted in the
calculation of angle of slope of regression lines (6),
the values, 62.5 8.2% and 60.7 18.0%, respec-
tively, are not significantly different. In 14 of the 17
patients in whom a2-macroglobulin was looked for,
this protein was demonstrable.
Figure 3 shows the effect of indomethacin on dif-
ferential protein clearances measured from albumin
and a2-macroglobulin in 14 patients. Selectivity in-
creases in 7 patients, remains constant in 3, and de-
creases in 4. There is no consistent effect on selec-
tivity during indomethacin medication measured
from albumin and 2-macroglobulin in the 14 pa-
tients. Classification into sodium-restricted and so-
dium-containing diet does not influence these re-
sults.
Fractional PVP clearances. In 24 out of the 28
patients in which fractional PVP clearances were
carried out before and during indomethacin, the
limit of the urine to plasma ratio was reached, and
regression lines could be calculated. The three
types of permeability slope, described by Hulme
and Hardwicke [53], were found. The first group
consisted of 3 patients with a permeability slope as
found in patients with normal renal function. Figure
4 shows that there is no difference in the slope be-
fore and during indomethacin medication. The cal-
culated regression lines hardly differed, as given in
Table 3. Endogenous creatinine clearance de-
creased in patients 1 and 3 during indomethacin
medication and remained constant in patient 2. An
effect on proteinuria was evident in all 3 patients.
The second group consisted of 5 patients with nor-
mal permeability to PVP up to 40 A but increased
relative clearance of PVP fractions above 40 A. Fig-
ure 5 shows the results in this group. The data con-
cerning patients 4 through 8 are given in Table 3.
The permeability slopes up to 40 A did not differ,
95 Control4
3
00
x
C-)
0
cc
50
100
Indomethacin
18 22 28 34 43 53 65
a Values are means SEM.
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but in 4 of the 5 patients the mean clearance of mol-
ecules larger than 40 A was significantly lower dur-
ing indomethacin medication, and in patient 4 the in-
creased permeability above 40 A even disappeared
completely. In patient 6, the permeability above 40
A increased. None of the patients in this group
showed an effect in endogenous creatinine clear-
ance; but in all 5, proteinuria decreased during med-
ication.
The third group consisted of the remaining 16 pa-
tients. All showed a decreased relative clearance of
molecules smaller than 40 A and increased per-
meability above 40 A. Figure 6 shows the results as
given in Table 3. Permeability up to 40 A did not
differ significantly. In 13 of the 16 patients, the
mean clearance of molecules, as percentage GFR,
above 40 A decreased during indomethacin medica-
tion, in 2 patients (9 and 24) permeability increased,
and in 1 patient (19) there was no difference. The
overall effect on permeability above 40 A is signifi-
cant (P < 0.01). In all patients, there was an effect
on proteinuria, but endogenous creatinine clearance
decreased in only 10 of the 16 patients to an appre-
ciable extent. Taking the three groups together, 21
Table 3. Fractional PVP clearances in 24 patients before and during indomethacinmedication
Patient Linear regression Clearance of PVP> 40 Aa Endogenous C, Proteinuria Serum albumin
no. Indomethacin (F) %GFR mi/mm g/24hr giliter
no 26.81 — 31.36x 107 4.8 35.8
yes 27.28 — 32.57x 64 1.6 38.5
2 no 28.15 — 35.63x 75 7.8 30.9
yes 27.26 — 33.39x 75 5.5 31.8
3 no 23.62 — 26.54x
—
73 ' 5.2 17.1
yes 23.61 — 27.03x 63 2.4 18.4
4 no 27.94 — 31.86x 0.32 0.22 85 7.3 19.0
yes 26.05 — 29.88x 0 88 4.5 20.6
5 no 29.25 — 35.60x 2.33 1.17 45 17.5 17.4
yes 30.04 — 35.89x 0.71 1.03 42 8.7 19.3
6 no 27.44 — 32.22x 0.24 0.06 118 4.8 35.8
yes 27.13 — 32.22x 1.12 0.04 120 1.6 38.5
7 no 28.64 — 34.50x 4.34 2.18 34 7.0 23.7
yes 29.79 — 35.59x 1.43 0.77 34 3.4 27.0
8 no 25.01 — 27.87x 5.57 3.29 88 3.2 39.5
yes 25.20 — 28.09x 0.56 0.13 86 1.9 39.5
9 no 25.41 — 30.29x 0.29 0.22 68 8.2 34.9
yes 25.76 — 30.19x 0.42 0.17 65 2.8 36.9
10 no 25.12 — 29.17x 1.44 0.93 44 5.8 29.9
yes 27.24 — 23.52x 1.16 0.90 40 3.6 31.3
11 no 25.94 — 32.73x 0.289 0.446 95 9.5 33.5
yes 27.56 — 34.41x 0,136 0.084 53 1.5 39.2
12 no 24.00 — 26.67x 1.23 0.34
yes 23.84 — 28.41x 0.32 0.15 110 3.4 25.8
13 no 23.53 — 27.33x 1.13 0.69 85 7.6 18.5
yes 21.78 — 24.83x 0.08 0.09 95 5.7 22.9
14 no 22.41 — 27,29x 0.25 0.21 90 9.2 38.9
yes 21.61 — 26.29x 0.06 0.04 90 1.2 34.4
15 no 23.07 — 25.43x 2.68 1.10 49 13.8 8.8
yes 21.73 — 23.33x 0.87 0.22 54 5.4 14.2
16 no 21.50 — 25.OOx 5.53 0.86 75 12.1 14.6
yes 22.10 — 26.50x 1.80 1.08 24 7.9 18.8
17 no 22.53 — 27,83x 0.38 0.20 133 5.5 31.0
yes 23.00 — 28.38x 0.16 0.09 95 1.9 32.0
18 no 25.70 — 3l.85x 1.51 0.66 96 6.3 28.9
yes 25.82 — 32.05x 0 94 2.7 32.7
19 no 21.70 — 23,94x 0.79 0.44 110 10.2 19.3
yes 23.60 — 27.OOx 0.82 0.46 78 2.9 29.1
20 no 18.62 — 20.68x 1.39 0.38 40 14.1 15.6
yes 21.30 — 23,68x 1.22 0.62 32 9.5 16.5
21 no 23.94 — 23.86x 0.43 0.14 55 8.1 40.2
yes 25.76 — 29.66x 0 45 4.3 38.6
22 no 22.83 — 24.33x 0.34 0.23 89 9.6 29.3
yes 21.19 — 24.86x 0.03 0.02 83 4.0 31.9
23 no 21.89 — 23.91x 0.62 0.22 54 8.4 40.2
yes 23.36 — 26,89x 0.28 0.21 43 4.3 38.2
24 no 17.05 — 17.50x 0.08 0.03 48 5.3 17.0
yes 19.60 — 19.56x 0.64 0.09 48 5.3 15.9
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Molecular radius, A
Fig. 5. Permeability slopes in five patients without and during
indo,nethacin medication (normal permeability to molecules
smaller than 40 A; increased permeability to molecules larger
than 40 A).
Molecular radius, A
Fig. 6. Per,neability slopes for PVP molecules in 16 patients,
without and during indomethacin medication (decreased per-
meability to molecules smaller than 40 A; increased permeability
to molecules larger than 40 A).
of the 24 patients showed an increased relative
clearance of PVP molecules larger than 40 A. Dur-
ing indomethacin medication, these relative clear-
ances decreased in 17 patients, increased in 3, and
remained unchanged in 1. For the entire group, this
effect is significant (P < 0.01). Considering the
mean PVP clearance as percentages of GFR for
molecules larger than 40 A in these 21 patients, the
mean clearance without indomethacin was 1.39
(sEM) 0.33% GFR, and during indomethacin it was
0.56 0.12% GFR. This difference is significant (P
< 0.02, Student's t test). Figure 7 gives the mean
clearance (% GFR) above 40 A in these 21 patients
plotted linearly on the Y axis. The effect is more
obvious than it is on probability scale.
Discussion
This study confirms the finding of others that in
patients with the nephrotic syndrome indomethacin
reduces proteinuria. With our patients, in contrast
to the results of Arisz et al [19], there was no signifi-
cant increase in selectivity of proteinuria. These au-
thors observed a consequent increase in selectivity
in 10 patients on sodium-restricted diet, but it may
be that the two studies are not comparable. Our pa-
tients had a more selective proteinuria before indo-
methacin treatment, and perhaps the effect on se-
lectivity is not obvious in the more selective pro-
teinurias. As a matter of fact, 4 of the 7 patients in
the sodium-restricted group with a decreasing selec-
tivity had a selectivity index before medication of
10% or less. Nevertheless, when the patients are di-
vided into selective and nonselective proteinuria,
whether concerning sodium restriction or not, there
is again no difference in effect on selectivity in both
groups. Of the 16 patients with selective protein-
uria, selectivity increased in 10, and of 17 patients
with nonselective proteinuria it increased also in 10
patients. So it may be that an effect of indomethacin
on selectivity in proteinuria is only consistent in pa-
tients with nonselective proteinuria and on a so-
dium-restricted diet. Additional determination of
transferrin and a2-macroglobulin does not add to
the information on selectivity of proteinuria. In this
study, there was no direct relation between the ef-
fect of indomethacin on proteinuria and its effect on
endogenous creatinine clearance. When GFR is
measured with 1251-sodium iothalamate, a mean de-
crease in GFR of 35% has been reported. We found
0
A
>
0
Fig. 7. Mean clearance percentage GFR of PVP molecules
larger than 40 A in 21 patients, without and during indomnethacin
,nedication.
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a mean decrease of 11% in the less accurate endog-
enous creatinine clearance given by the fact that
measuring GFR by a corrected constant infusion
method with iothalamate is more exact [54] and also
by the difference in the time of measurement. The
greatest rise in serum creatinine or fall in endoge-
nous creatinine clearance is often seen on day 2 or 3
of indomethacin medication, and GFRwas measured
on day 3 by Arisz et al. On the contrary, in this study
the mean clearance over a 5-day period was deter-
mined, including the sometimes manifest increase
in creatinine clearance on days 4 and 5.
Indomethacin decreases the relative fractional
clearances of PVP molecules above 40 A, whereas
there is no consistent effect registrated on mole-
cules between 18 and 40 A. This effect is again not
related to an effect on proteinuria or endogenous
creatinine clearance, nor is a correlation found be-
tween the type of permeability slope and the patho-
logic diagnosis or the serum albumin concentration.
The discrepancy between the effects on selectivity
of proteinuria and on fractional PVP clearances
may be effectuated by the less reliable method of
determining relative protein clearances or in dif-
ferences in shape and electrical charge between
PVP and protein molecules [33, 55]. Differences in
physical properties have also been mentioned, as
polymerization of protein molecules [56—58]. Re-
cent research has revealed that in Wistar rats with
nephrotoxic glomerulonephritis the permeability to
dextran sulphate molecules with a negative charge
is increased, whereas that of neutral dextran of
equivalent radius is decreased in relation to the per-
meability in normal rats [39, 41, 59]. These experi-
ments, however, were carried out with dextran
fractions of 18 to 42 A, and so far there are no re-
sults with larger molecules. The glomerular macro-
molecular permeability studies with polydisperse
'251-PVP have confirmed the earlier observations of
an increased fractional clearance of macromole-
cules larger than 40 A in patients with the nephrotic
syndrome. The fractional clearance of smaller mac-
romolecules is either within the normal range or is
impaired. This could suggest that there is no gener-
alized increase in glomerular permeability, and only
a proportion of the available filtration membrane
has been altered. If one assumes the normal gb-
merular basement membrane to behave as though it
were porous with all the pores of equal diameter
[33-36], one could devise mathematical models
where a portion of the membrane has pores of in-
creased diameter [60]. In the simple two-pore hy-
pothesis the ratio of larger to smaller pores deter-
mines the increased relative fractional clearance of
polymer larger than 40 A; likewise, a reduction in
the relative fractional clearance of such polymer
would be associated with a reduction in the propor-
tion of larger pores in the altered membrane. The
studies reported here have demonstrated that indo-
methacin decreases the relative fractional clear-
ances of PVP molecules larger than 40 A from a
mean of 1.39 0.33% GFR prior to treatment to
0.56 0.12% GFR while on treatment. This reduc-
tion is associated with a fall in proteinuria from a
mean of 9.2 5.6 to 4.6 3.8 g124 hr. This effect of
indomethacin on permeability to PVP above 40 A
prompts comparison with a recent study [61] in rats
given angiotensin infusions, in which permeability
to larger molecules increased, as well as protein-
uria, in accordance with a reduction in GFR, an
even greater reduction in RPF, and consequently
an increase in filtration fraction. The effect of
indomethacin could be the opposite of this ef-
fect. One might assume that hyperangiotensine-
mia in patients with the nephrotic syndrome results
in an increase in proteinuria and in permeability to
PVP above 40 A. Lowering angiotensin activity
might result in a decrease in proteinuria and a de-
creased clearance of PVP, larger than 40 A. As a
matter of fact, indomethacin lowers PRA in normal
volunteers and patients with various renal diseases
[19, 62], resulting in a lowering of GFR, a moderate
decrease in RPF, and a decrease in filtration
fraction. It is attractive to correlate the decrease
in filtration fraction with a decreased permeabil-
ity to macromolecules in situations where fil-
tration equlibrium is not attained, the more,
because this correlation is mathematically calcu-
lated [33-37] and indomethacin and the renin angio-
tensin system influence the GFRJRPF ratio. It has
to be mentioned that a lower oncotic pressure of the
arterial plasma, as in hypoalbuminemia, also influ-
ences filtration fraction in such a way that filtration
equilibrium is later or never attained, leading to a
decrease in filtration fraction [63]. A further analy-
sis of these hemodynamic factors can only be made
by measuring glomerular transcapillary pressures
and plasma flow rates, not only in superficial neph-
rons but also in juxtamedullary ones. Until now, it
has not been proven that changes in single nephron
filtration fraction may be extrapolated to total kid-
ney hemodynamics [46-50]. Although the renin an-
giotensin system and the renal prostaglandins influ-
ence the distribution of intrarenal blood flow, it is
not clear that the effect of indomethacin on protein-
uria and permeability to PVP molecules larger than
40 A is realized by altering single nephron hemo-
dynamics, by redistribution of blood flow to neph-
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rons with a greater capacity, or by both mecha-
nisms in combination. We found no support that
indomethacin influences the pore radius or sieving
structure of the glomerulus membrane, given the
result that there is no complete shift over the whole
range of macromolecular permeability, unless only
areas with the damaged greater pores are affected
and partly occluded. Likewise, we found no support
that electrical charge of the glomerular polyanion
is affected, because such an effect would not alter
the permeability to only a part of the neutral PVP
molecules. Finally, the observed acute effects of
indomethacin and its reversibility after discontinu-
ation of the drug cannot be accounted for by a limit-
ing of the pathologic process in the glomeruli as
such.
Conclusion. It is presumed that indomethacin
exerts its effects on proteinuria, and on per-
meability to macromolecules such as PVP, by influ-
encing intrarenal and glomerular hemodynamics.
The effects of indomethacin on the GFRIRPF ratio
and on PRA imply this mechanism. So does the
well-known prostaglandins-synthetase-inhibiting ef-
fect of indomethacin, which can interfere with renal
prostaglandins and the renal angiotensin system as
mediators of intrarenal and glomerular hemody-
namics.
Reprint requests to Dr. R. G. W. L. Tiggeler, Department of
Medicine, Division of Nephrology, University of N(jmegen, The
Netherlands.
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